Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients
Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dos...
Gespeichert in:
| Veröffentlicht in: | Transplantation 2007-06, Vol.83 (12), p.1648-1651 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1651 |
|---|---|
| container_issue | 12 |
| container_start_page | 1648 |
| container_title | Transplantation |
| container_volume | 83 |
| creator | ALLOWAY, Rita STEINBERG, Steven WISEMANDLE, Kathleen FITZSIMMONS, William FIRST, M. Roy KHALIL, Kassem GOURISHANKAR, Sita MILLER, Joshua NORMAN, Douglas HARIHARAN, Sundaram PIRSCH, John MATAS, Arthur ZAITZMAN, Jeffrey |
| description | Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day. |
| doi_str_mv | 10.1097/01.tp.0000264056.20105.b4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70657315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70657315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-d8ff908286ba08e82980418799e21d815f0765fd8eb6fe6d42f7a385db999b813</originalsourceid><addsrcrecordid>eNpFkc2OFCEUhYnROG3rKxhc6K5KqCoKWJrJ-JNM4mZcEyguE5SCEii138MHlnE6aTYs-M7hnnsQekNJT4nk7wnt69aTdoZ5ImzuB0IJ6830BB0oG6duJoI8RQdCJtrRceRX6EUp3xvPRs6foyvKmZAjowf09-53wifQueAtlbqk-Aty8Slil9OKNd5yus_adUYXsDjDvV8h4praU4oLdFb7cMJVLzkFv-4Fw58K0YLtMgRoIuxSXveg64Opj7hUbQLgH95GaMKsY9mCjrV5L37zEGt5iZ45HQq8Ot9H9O3jzd315-7266cv1x9uu2Wah9pZ4ZwkYhCz0USAGKRogQWXEgZqBWWO8Jk5K8DMDmY7DY7rUTBrpJRG0PGI3j36tpA_dyhVrb4sENo4kPaiOJkZH9tGj0g-gi1lKRmc2rJfdT4pStRDJYpQVTd1qUT9r0SZqWlfnz_ZzQr2ojx30IC3Z0CXRQfXNrL4cuGEaLmIHP8BT6eZEw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70657315</pqid></control><display><type>article</type><title>Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>ALLOWAY, Rita ; STEINBERG, Steven ; WISEMANDLE, Kathleen ; FITZSIMMONS, William ; FIRST, M. Roy ; KHALIL, Kassem ; GOURISHANKAR, Sita ; MILLER, Joshua ; NORMAN, Douglas ; HARIHARAN, Sundaram ; PIRSCH, John ; MATAS, Arthur ; ZAITZMAN, Jeffrey</creator><creatorcontrib>ALLOWAY, Rita ; STEINBERG, Steven ; WISEMANDLE, Kathleen ; FITZSIMMONS, William ; FIRST, M. Roy ; KHALIL, Kassem ; GOURISHANKAR, Sita ; MILLER, Joshua ; NORMAN, Douglas ; HARIHARAN, Sundaram ; PIRSCH, John ; MATAS, Arthur ; ZAITZMAN, Jeffrey</creatorcontrib><description>Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/01.tp.0000264056.20105.b4</identifier><identifier>PMID: 17589351</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - pharmacokinetics ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation - immunology ; Medical sciences ; Pharmacology. Drug treatments ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tacrolimus - administration & dosage ; Tacrolimus - pharmacokinetics ; Tacrolimus - therapeutic use ; Tissue, organ and graft immunology</subject><ispartof>Transplantation, 2007-06, Vol.83 (12), p.1648-1651</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-d8ff908286ba08e82980418799e21d815f0765fd8eb6fe6d42f7a385db999b813</citedby><cites>FETCH-LOGICAL-c462t-d8ff908286ba08e82980418799e21d815f0765fd8eb6fe6d42f7a385db999b813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18898009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17589351$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ALLOWAY, Rita</creatorcontrib><creatorcontrib>STEINBERG, Steven</creatorcontrib><creatorcontrib>WISEMANDLE, Kathleen</creatorcontrib><creatorcontrib>FITZSIMMONS, William</creatorcontrib><creatorcontrib>FIRST, M. Roy</creatorcontrib><creatorcontrib>KHALIL, Kassem</creatorcontrib><creatorcontrib>GOURISHANKAR, Sita</creatorcontrib><creatorcontrib>MILLER, Joshua</creatorcontrib><creatorcontrib>NORMAN, Douglas</creatorcontrib><creatorcontrib>HARIHARAN, Sundaram</creatorcontrib><creatorcontrib>PIRSCH, John</creatorcontrib><creatorcontrib>MATAS, Arthur</creatorcontrib><creatorcontrib>ZAITZMAN, Jeffrey</creatorcontrib><title>Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.</description><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Delayed-Action Preparations</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - pharmacokinetics</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation - immunology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Tacrolimus - administration & dosage</subject><subject>Tacrolimus - pharmacokinetics</subject><subject>Tacrolimus - therapeutic use</subject><subject>Tissue, organ and graft immunology</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkc2OFCEUhYnROG3rKxhc6K5KqCoKWJrJ-JNM4mZcEyguE5SCEii138MHlnE6aTYs-M7hnnsQekNJT4nk7wnt69aTdoZ5ImzuB0IJ6830BB0oG6duJoI8RQdCJtrRceRX6EUp3xvPRs6foyvKmZAjowf09-53wifQueAtlbqk-Aty8Slil9OKNd5yus_adUYXsDjDvV8h4praU4oLdFb7cMJVLzkFv-4Fw58K0YLtMgRoIuxSXveg64Opj7hUbQLgH95GaMKsY9mCjrV5L37zEGt5iZ45HQq8Ot9H9O3jzd315-7266cv1x9uu2Wah9pZ4ZwkYhCz0USAGKRogQWXEgZqBWWO8Jk5K8DMDmY7DY7rUTBrpJRG0PGI3j36tpA_dyhVrb4sENo4kPaiOJkZH9tGj0g-gi1lKRmc2rJfdT4pStRDJYpQVTd1qUT9r0SZqWlfnz_ZzQr2ojx30IC3Z0CXRQfXNrL4cuGEaLmIHP8BT6eZEw</recordid><startdate>20070627</startdate><enddate>20070627</enddate><creator>ALLOWAY, Rita</creator><creator>STEINBERG, Steven</creator><creator>WISEMANDLE, Kathleen</creator><creator>FITZSIMMONS, William</creator><creator>FIRST, M. Roy</creator><creator>KHALIL, Kassem</creator><creator>GOURISHANKAR, Sita</creator><creator>MILLER, Joshua</creator><creator>NORMAN, Douglas</creator><creator>HARIHARAN, Sundaram</creator><creator>PIRSCH, John</creator><creator>MATAS, Arthur</creator><creator>ZAITZMAN, Jeffrey</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070627</creationdate><title>Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients</title><author>ALLOWAY, Rita ; STEINBERG, Steven ; WISEMANDLE, Kathleen ; FITZSIMMONS, William ; FIRST, M. Roy ; KHALIL, Kassem ; GOURISHANKAR, Sita ; MILLER, Joshua ; NORMAN, Douglas ; HARIHARAN, Sundaram ; PIRSCH, John ; MATAS, Arthur ; ZAITZMAN, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-d8ff908286ba08e82980418799e21d815f0765fd8eb6fe6d42f7a385db999b813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Delayed-Action Preparations</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - pharmacokinetics</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation - immunology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Tacrolimus - administration & dosage</topic><topic>Tacrolimus - pharmacokinetics</topic><topic>Tacrolimus - therapeutic use</topic><topic>Tissue, organ and graft immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ALLOWAY, Rita</creatorcontrib><creatorcontrib>STEINBERG, Steven</creatorcontrib><creatorcontrib>WISEMANDLE, Kathleen</creatorcontrib><creatorcontrib>FITZSIMMONS, William</creatorcontrib><creatorcontrib>FIRST, M. Roy</creatorcontrib><creatorcontrib>KHALIL, Kassem</creatorcontrib><creatorcontrib>GOURISHANKAR, Sita</creatorcontrib><creatorcontrib>MILLER, Joshua</creatorcontrib><creatorcontrib>NORMAN, Douglas</creatorcontrib><creatorcontrib>HARIHARAN, Sundaram</creatorcontrib><creatorcontrib>PIRSCH, John</creatorcontrib><creatorcontrib>MATAS, Arthur</creatorcontrib><creatorcontrib>ZAITZMAN, Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ALLOWAY, Rita</au><au>STEINBERG, Steven</au><au>WISEMANDLE, Kathleen</au><au>FITZSIMMONS, William</au><au>FIRST, M. Roy</au><au>KHALIL, Kassem</au><au>GOURISHANKAR, Sita</au><au>MILLER, Joshua</au><au>NORMAN, Douglas</au><au>HARIHARAN, Sundaram</au><au>PIRSCH, John</au><au>MATAS, Arthur</au><au>ZAITZMAN, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>2007-06-27</date><risdate>2007</risdate><volume>83</volume><issue>12</issue><spage>1648</spage><epage>1651</epage><pages>1648-1651</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>Tacrolimus extended-release (XL) is a once-daily formulation recently developed to reduce the frequency of dosing for patients currently using the twice-a-day formulation of tacrolimus (TAC). As reported previously, 67 kidney transplant recipients were safely converted (1:1 mg basis, total daily dose) from TAC twice-a-day to XL once-daily in the morning and were maintained on an am dosing regimen of XL using the same therapeutic monitoring and patient care techniques currently employed with TAC. The 2-year postconversion patient (100%) and graft (98.5%) survival, incidence of biopsy-confirmed acute rejection (6.0%), incidence of multiple rejections (1.5%), and safety profile (posttransplant diabetes, hyperlipidemia, hypertension, infections, renal dysfunction, hepatic dysfunction, and malignancies) were consistent with or more favorable than those previously reported for TAC twice-a-day.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>17589351</pmid><doi>10.1097/01.tp.0000264056.20105.b4</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1337 |
| ispartof | Transplantation, 2007-06, Vol.83 (12), p.1648-1651 |
| issn | 0041-1337 1534-6080 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70657315 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Delayed-Action Preparations Dose-Response Relationship, Drug Drug Administration Schedule Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Kidney Transplantation - immunology Medical sciences Pharmacology. Drug treatments Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Tacrolimus - administration & dosage Tacrolimus - pharmacokinetics Tacrolimus - therapeutic use Tissue, organ and graft immunology |
| title | Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A29%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20years%20postconversion%20from%20a%20prograf-based%20regimen%20to%20a%20once-daily%20tacrolimus%20extended-release%20formulation%20in%20stable%20kidney%20transplant%20recipients&rft.jtitle=Transplantation&rft.au=ALLOWAY,%20Rita&rft.date=2007-06-27&rft.volume=83&rft.issue=12&rft.spage=1648&rft.epage=1651&rft.pages=1648-1651&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/01.tp.0000264056.20105.b4&rft_dat=%3Cproquest_cross%3E70657315%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70657315&rft_id=info:pmid/17589351&rfr_iscdi=true |